We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+16.43%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.58B
AUM Growth
+$403M
Cap. Flow
+$220M
Cap. Flow %
13.93%
Top 10 Hldgs %
32.67%
Holding
149
New
11
Increased
79
Reduced
34
Closed
11

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$13M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$11.7M
3
PACB icon
Pacific Biosciences
PACB
+$11M
4
MDT icon
Medtronic
MDT
+$8.74M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$8.4M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$24.7M
2
BHC icon
Bausch Health
BHC
+$3.02M
3
AMGN icon
Amgen
AMGN
+$2.16M
4
GILD icon
Gilead Sciences
GILD
+$1.72M
5
KTWO
K2M Group Holdings, Inc
KTWO
+$1.43M

Sector Composition

Rank Sector Weight
1 Healthcare 93.18%
2 Industrials 1.09%
3 Technology 0.34%
4 Financials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNMK
51
DELISTED
GenMark Diagnostics, Inc
GNMK
$9.85M 0.62%
1,339,502
+153,000
+13% +$1.12M
CDNA icon
52
CareDx
CDNA
$2.05B
$9.72M 0.62%
+337,049
New +$6.31M
IART icon
53
Integra LifeSciences
IART
$1.5B
$9.33M 0.59%
141,620
+83,459
+143% +$5.19M
WCG
54
DELISTED
Wellcare Health Plans, Inc.
WCG
$9.06M 0.57%
28,269
+6,219
+28% +$1.77M
GMED icon
55
Globus Medical
GMED
$10.5B
$8.59M 0.54%
151,251
+77,206
+104% +$4.06M
TMO icon
56
Thermo Fisher Scientific
TMO
$198B
$8.41M 0.53%
34,471
+5,340
+18% +$1.23M
VRTX icon
57
Vertex Pharmaceuticals
VRTX
$123B
$7.8M 0.5%
40,494
-1,800
-4% -$321K
AMGN icon
58
Amgen
AMGN
$198B
$7.66M 0.49%
36,950
-10,950
-23% -$2.16M
OMCL icon
59
Omnicell
OMCL
$2.09B
$7.52M 0.48%
104,650
+40,705
+64% +$2.56M
MOH icon
60
Molina Healthcare
MOH
$11.7B
$7.51M 0.48%
50,478
-1,762
-3% -$225K
HMSY
61
DELISTED
HMS Holdings Corp.
HMSY
$7.45M 0.47%
227,020
+80,951
+55% +$2.34M
TRHC
62
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
$7.05M 0.45%
86,884
+19,578
+29% +$1.43M
XENT
63
DELISTED
Intersect ENT, Inc
XENT
$6.73M 0.43%
234,227
+146,199
+166% +$4.39M
QTRX icon
64
Quanterix
QTRX
$182M
$6.71M 0.43%
313,230
+147,750
+89% +$2.34M
IRTC icon
65
iRhythm Holdings
IRTC
$3.64B
$6.59M 0.42%
69,661
+23,740
+52% +$2.07M
COO icon
66
Cooper Companies
COO
$14B
$6.32M 0.4%
91,244
+14,044
+18% +$902K
IDXX icon
67
Idexx Laboratories
IDXX
$44.8B
$6.07M 0.38%
24,307
+17,307
+247% +$4.2M
INGN icon
68
Inogen
INGN
$178M
$5.68M 0.36%
23,261
+17,250
+287% +$3.99M
QTNT
69
DELISTED
Quotient Limited Ordinary Shares
QTNT
$5.45M 0.35%
18,046
+10,051
+126% +$3.02M
HCA icon
70
HCA Healthcare
HCA
$82.3B
$5.13M 0.33%
36,888
+17,888
+94% +$2.23M
NBIX icon
71
Neurocrine Biosciences
NBIX
$17.2B
$5.11M 0.32%
41,550
-2,000
-5% -$227K
QGEN icon
72
Qiagen
QGEN
$8.49B
$5.08M 0.32%
126,548
+54,085
+75% +$2.16M
TFX icon
73
Teleflex
TFX
$5.96B
$4.73M 0.3%
17,792
+3,792
+27% +$983K
BMRN icon
74
BioMarin Pharmaceuticals
BMRN
$11.5B
$4.64M 0.29%
47,869
-1,650
-3% -$165K
NVRO
75
DELISTED
NEVRO CORP.
NVRO
$4.58M 0.29%
80,415
+54,617
+212% +$3.41M
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2018 Portfolio in Review

As of Q3 2018, Bellevue Group held 149 positions worth $1.58B, up 34% from $1.17B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group deployed $220M of net new capital in Q3 2018, opening 11 new positions and adding to 79 existing holdings. Its largest new stake was Pacific Biosciences: 2,575,000 shares worth $13.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was DexCom, an estimated $24.7M trimmed.

  • Bellevue Group's largest Q3 2018 buy was Pacific Biosciences: 2,575,000 shares worth $13.9M.
  • Bellevue Group added most to Abbott in Q3 2018, an estimated $13M increase.
  • Bellevue Group's biggest Q3 2018 reduction was DexCom, cutting an estimated $24.7M.
  • Bellevue Group fully exited Bausch Health in Q3 2018, selling an estimated $3.02M.
  • Bellevue Group's ten largest holdings make up 33% of its $1.58B portfolio in Q3 2018.
  • Bellevue Group opened 11 new positions and closed 11 in Q3 2018.
  • Bellevue Group's portfolio value rose 34% quarter-over-quarter to $1.58B.

Based on Bellevue Group's 13F filing for Q3 2018, filed 13 Nov 2018.